{"gene":"MIF","run_date":"2026-06-10T02:59:50","timeline":{"discoveries":[{"year":2003,"finding":"CD74, a Type II transmembrane protein, is a high-affinity receptor for MIF. MIF binds to the extracellular domain of CD74 with a dissociation constant of ~9×10⁻⁹ M (by surface plasmon resonance), and CD74 is required for MIF-induced ERK1/2 MAP kinase activation, cell proliferation, and PGE2 production.","method":"Expression cloning, surface plasmon resonance (BIAcore), functional cell-based assays with soluble CD74 as inhibitor","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — expression cloning plus quantitative binding assay (SPR) plus functional rescue/inhibition experiments; widely replicated across multiple subsequent studies","pmids":["12782713"],"is_preprint":false},{"year":1994,"finding":"Recombinant human and mouse MIF are bioactive 12.5 kDa proteins with no significant post-translational modifications; both inhibit monocyte migration, induce TNF-α secretion, and stimulate nitric oxide production by IFN-γ-primed macrophages. Circular dichroism reveals significant β-sheet and α-helix secondary structure.","method":"Recombinant protein expression and purification, gel electrophoresis, mass spectrometry, bioactivity assays (Boyden chamber, cytokine ELISA), circular dichroism spectroscopy, guanidine denaturation","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — multiple orthogonal biochemical and functional methods in a single rigorous study; foundational characterization replicated broadly","pmids":["7947826"],"is_preprint":false},{"year":2009,"finding":"MIF triggers leukocyte recruitment through CXCR4; CD74 forms functional heteromeric complexes with CXCR4 at the cell surface of monocytes, and MIF-stimulated CD74-dependent AKT activation is blocked by anti-CXCR4 antibody and AMD3100, whereas CXCL12-stimulated AKT activation is not blocked by anti-CD74, indicating MIF-specific signaling through the CD74/CXCR4 complex.","method":"Co-immunoprecipitation of endogenous CD74/CXCR4 complexes from monocytes; HEK293 overexpression; receptor-specific antibody and small-molecule inhibitor blockade; AKT phosphorylation assay","journal":"FEBS letters","confidence":"High","confidence_rationale":"Tier 2 / Moderate — reciprocal co-IP from primary monocytes plus functional inhibition with two orthogonal blockers (antibody and AMD3100), single lab","pmids":["19665027"],"is_preprint":false},{"year":2009,"finding":"MIF-induced neutrophil accumulation in the alveolar space is mediated through CD74 expressed on alveolar macrophages, which activates p44/p42 MAPK and chemokine (MIP-2) release; anti-CD74 antibody inhibits MIF-induced MAPK phosphorylation, MIP-2 release, and neutrophil accumulation in vivo.","method":"Intratracheal instillation of recombinant MIF in mice ± anti-CD74 antibody or ISO-1; macrophage culture; ELISA; BAL cell counting","journal":"Respiratory research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo and in vitro loss-of-function with defined cellular phenotype; single lab, two complementary readouts","pmids":["19413900"],"is_preprint":false},{"year":2008,"finding":"CD74 acts as a functional receptor for MIF in human podocytes; MIF binding to CD74 leads to phosphorylation of ERK1/2 and p38, and MIF induces expression of TRAIL and MCP-1 in podocytes and proximal tubule cells in a p38-dependent manner. High glucose and TNF-α upregulate CD74 surface expression.","method":"Cell surface CD74 expression by flow cytometry; MIF stimulation of cultured podocytes; Western blot for ERK1/2 and p38 phosphorylation; cytokine ELISA; pharmacological inhibition of p38","journal":"Journal of the American Society of Nephrology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — cell-based mechanistic experiments with phosphorylation readouts and pharmacological pathway inhibition; single lab","pmids":["18842989"],"is_preprint":false},{"year":2016,"finding":"MIF increases CD44 expression in synovial fibroblasts, promotes CD44 recruitment into a functional CD74/CD44 signal transduction complex, and stimulates alternative exon splicing to produce CD44v3-v6 isoforms associated with invasive phenotypes. CD44 recruitment, downstream MAPK and RhoA signaling, and invasive phenotype all require MIF and CD74.","method":"MIF stimulation of synovial fibroblasts; Western blot; co-immunoprecipitation; RT-PCR splicing analysis; RhoA activity assay; invasion assay; MIF pathway antagonist treatment and shRNA knockdown","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP plus functional rescue/inhibition with multiple readouts; single lab, human allele correlation","pmids":["27872288"],"is_preprint":false},{"year":2016,"finding":"MIF-CD74 signaling inhibits IFN-γ secretion in microglia through phosphorylation of ERK1/2, thereby suppressing microglial M1 polarization; siRNA-mediated knockdown or antibody neutralization of MIF or CD74 promotes IFN-γ release, induces M2→M1 shift, and prolongs survival in glioma-implanted mice.","method":"siRNA knockdown; antibody neutralization; Western blot for ERK1/2 phosphorylation; cytokine ELISA; in vivo glioma implantation model; survival analysis","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro mechanistic signaling data combined with in vivo functional validation; single lab","pmids":["27157615"],"is_preprint":false},{"year":2002,"finding":"MIF secretion is induced by cell adhesion to fibronectin in quiescent fibroblasts; secreted MIF acts as an autocrine mediator of integrin-dependent MAP kinase activation, cyclin D1 expression, and DNA synthesis. MIF secretion requires protein kinase C activity, and MIF-deficient cells show significantly higher Rb tumor suppressor and lower E2F transcriptional activities.","method":"MIF-null mouse fibroblasts; recombinant MIF reconstitution; PKC inhibition; Western blot; cyclin D1 reporter; DNA synthesis assay; Rb/E2F activity assays","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO cells with reconstitution and pharmacological inhibition; single lab, multiple readouts","pmids":["12297513"],"is_preprint":false},{"year":2015,"finding":"MIF is O-GlcNAcylated at Ser112/Thr113 at its C-terminus; the naturally secreted O-GlcNAcylated MIF binds to EGFR and inhibits EGF binding and EGF-induced EGFR activation, ERK and c-Jun phosphorylation, cell invasion, proliferation, and brain tumor formation. EGFR activation enhances secretion of MMP13, which degrades extracellular MIF, creating a feedforward loop.","method":"Mass spectrometry identification of O-GlcNAcylation site; binding assays (MIF-EGFR interaction); functional assays (proliferation, invasion, tumor formation); site-directed mutagenesis at Ser112/Thr113; MMP13 secretion assay","journal":"Nature cell biology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — mass spectrometry PTM identification, mutagenesis, in vitro binding, and in vivo tumor model; single lab but multiple orthogonal methods","pmids":["26280537"],"is_preprint":false},{"year":2021,"finding":"MIF is a 3' flap nuclease that translocates to the nucleus during S phase; PARP1 co-localizes with MIF at the DNA replication fork, and MIF nuclease activity is required to resolve replication stress. MIF loss causes increased mutation frequency, cell cycle delays, and inhibition of DNA synthesis that cannot be rescued by nuclease-deficient MIF mutant.","method":"In vitro nuclease assay; nuclear fractionation; co-localization by imaging; cell cycle analysis; DNA synthesis assay; mutant MIF rescue experiment; cancer cell MIF knockdown","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro enzymatic reconstitution with mutagenesis validation plus cell-based rescue experiments using nuclease-dead mutant; single lab but multiple methods","pmids":["34012010"],"is_preprint":false},{"year":2016,"finding":"The transcription factor ICBP90 (UHRF1) is the major nuclear protein interacting with the MIF -794 CATT5-8 microsatellite promoter region and is essential for MIF transcription in monocytes/macrophages, B and T lymphocytes, and synovial fibroblasts; TLR-induced MIF transcription is regulated in an ICBP90- and CATT repeat length-dependent manner.","method":"Oligonucleotide affinity chromatography; LC-MS/MS protein identification; ICBP90 shRNA knockdown; promoter reporter assays; whole-genome transcription analysis","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — affinity chromatography + mass spectrometry identification, shRNA functional validation, genome-wide transcriptomic confirmation; single lab, multiple orthogonal methods","pmids":["26752645"],"is_preprint":false},{"year":2006,"finding":"Hypoxia-induced MIF expression is driven by HIF-1α through a hypoxia response element (HRE) in the 5'UTR of the MIF gene, and this expression is further modulated by CREB; hypoxia-induced degradation of CREB amplifies HIF-1-driven MIF transcription.","method":"HIF-1α overexpression; HRE reporter assay; CREB expression modulation; promoter deletion analysis; RT-PCR","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — promoter reporter assays with deletion constructs and defined transcription factor manipulation; single lab","pmids":["16854377"],"is_preprint":false},{"year":2018,"finding":"Soluble CD74 (sCD74) reroutes MIF/CXCR4/AKT-mediated survival of cardiac myofibroblasts to necroptosis via RIP1/RIP3-dependent pathway; sCD74 diminishes MIF-mediated AKT activation and triggers p38 activation, and co-treatment with MIF and sCD74 induces interferon-stimulated gene upregulation.","method":"Recombinant MIF + sCD74 co-treatment of primary cardiac fibroblasts; Western blot for AKT and p38; RIP1/RIP3 inhibitor studies; microarray + RT-qPCR gene expression","journal":"Journal of the American Heart Association","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — primary cell mechanistic experiments with pharmacological pathway inhibition and gene expression profiling; single lab","pmids":["30371153"],"is_preprint":false},{"year":2017,"finding":"MIF directly binds to and inhibits the proteolytic activity of the serine protease HTRA1, making MIF the first identified endogenous inhibitor of HTRA1. Both proteins are co-expressed in astrocytes and the interaction modulates availability of growth factors and extracellular matrix molecules affecting cell growth and differentiation.","method":"Co-immunoprecipitation; in vitro protease activity assay with MIF as inhibitor; immunohistochemistry co-localization in astrocytes","journal":"Cellular and molecular life sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP binding identification plus in vitro enzymatic inhibition assay; single lab, two orthogonal methods","pmids":["28726057"],"is_preprint":false},{"year":2022,"finding":"HDAC6 deacetylates MIF at K78; HDAC6 inhibition or aspirin treatment promotes MIF acetylation at K78, which suppresses the interaction between MIF and AIF (apoptosis-inducing factor), thereby impairing MIF nuclear translocation in ischemic cortical neurons and reducing neuronal DNA fragmentation and death.","method":"Mass spectrometry identification of K78 acetylation; co-immunoprecipitation of MIF-AIF interaction; MIF K78Q acetylation-mimetic knock-in mice; HDAC6 genetic ablation and pharmacological inhibition; fractionation for nuclear localization","journal":"Cell death & disease","confidence":"High","confidence_rationale":"Tier 1 / Moderate — MS-identified PTM site confirmed by mutagenesis knock-in mice, co-IP interaction studies, and subcellular fractionation; single lab, multiple orthogonal methods","pmids":["35585040"],"is_preprint":false},{"year":2024,"finding":"MIF directly binds PINK1, disrupting the PINK1-Parkin protein interaction; this blocks Parkin recruitment to mitochondria and inhibits mitophagy initiation in renal tubular epithelial cells, leading to apoptosis that can be reversed by the MIF inhibitor ISO-1.","method":"Co-immunoprecipitation of MIF-PINK1 interaction; MIF inhibition (ISO-1) and overexpression; Western blot for PINK1-Parkin interaction; mitophagy flux assays; apoptosis assay","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct protein interaction by co-IP combined with functional rescue; single lab","pmids":["38956064"],"is_preprint":false},{"year":2016,"finding":"RORα (nuclear receptor) directly occupies the MIF promoter region in THP-1 monocytes and HUVEC cells, and RORα ligand treatment modulates MIF expression, identifying MIF as a direct transcriptional target of RORα.","method":"Chromatin immunoprecipitation (ChIP) assay; RORα-specific ligand (CPG 52608, SR1001) treatment; RT-PCR gene expression analysis","journal":"Cell biology international","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP demonstrates direct promoter occupancy and ligand treatment confirms functional regulation; single lab","pmids":["27925372"],"is_preprint":false},{"year":2014,"finding":"MIF and its homolog D-DT synergistically inhibit steady-state p53 phosphorylation, stabilization, and transcriptional activity; combined siRNA loss of MIF and D-DT leads to dramatically reduced cell cycle progression, anchorage independence, focus formation, and increased apoptosis compared to individual loss. The p53 activation is dependent on reactive oxygen species (ROS) that mediate aberrant AMPK activation in MIF/D-DT-deficient cells.","method":"siRNA dual knockdown of MIF and D-DT; Western blot for p53 phosphorylation; cell cycle analysis; focus formation and soft-agar assays; ROS measurement; AMPK inhibitor experiments","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic loss-of-function with multiple functional readouts and pathway dissection; single lab","pmids":["24932684"],"is_preprint":false},{"year":2005,"finding":"MIF loss delays Myc-induced B-cell lymphoma development in vivo by perturbing E2F DNA-binding activity and enhancing p53 pathway tumor suppressor activity; MIF-deficient premalignant B-cells show delayed S-phase progression and increased apoptosis, and MIF-deficient lymphomas that do arise carry ARF deletions and p53 inactivating mutations.","method":"Eμ-Myc lymphoma mouse model with MIF-null background; E2F DNA-binding activity assay; p53 pathway activity; cell cycle analysis; tumor onset kinetics","journal":"Cell death and differentiation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic epistasis in vivo with molecular mechanism (E2F/p53) characterization; single lab","pmids":["15947793"],"is_preprint":false},{"year":2009,"finding":"MIF acts as an autocrine growth factor in pancreatic cancer cells; siRNA-mediated MIF silencing reduces MIF protein >85%, inhibits cellular proliferation, induces apoptosis, and is accompanied by increased AKT phosphorylation at Thr308.","method":"siRNA knockdown; qRT-PCR; Western blot; FACS apoptosis assay; AKT phosphorylation Western blot","journal":"The Journal of surgical research","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single-method KD with phenotype but limited pathway mechanistic depth; single lab","pmids":["19726058"],"is_preprint":false},{"year":2024,"finding":"CD74 is upregulated on activated CD4+ T cells by post-translational modification (chondroitin sulfate addition) and can be detected on the cell surface; CD74/CXCR4 heterocomplexes on activated CD4+ T cells are visualized by proximity ligation assay, and both CD74 and CXCR4 are causally involved in MIF-induced CD4+ T-cell migration as shown by receptor-specific inhibitors in 3D live cell imaging.","method":"Flow cytometry; Western blot; proximity ligation assay; 3D-matrix live cell imaging; receptor-specific pathway inhibitors; reanalysis of RNA-seq and proteomics datasets","journal":"Cellular and molecular life sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — proximity ligation for complex detection combined with functional migration assay using inhibitors; single lab, multiple orthogonal methods","pmids":["38992165"],"is_preprint":false},{"year":2013,"finding":"CD74 is required for MIF's inhibitory effect on osteoclastogenesis; MIF inhibits osteoclast formation from wild-type but not CD74-knockout bone marrow cultures, and CD74-deficient mice show decreased bone mass, increased osteoclast number and area, and reduced NFATc1 and c-Fos expression upon MIF treatment.","method":"CD74 knockout mice; in vitro osteoclast differentiation assay; micro-CT; histomorphometry; Western blot for NFATc1 and c-Fos","journal":"Journal of bone and mineral research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO with in vitro rescue and in vivo bone phenotype, molecular pathway confirmation; single lab","pmids":["23044992"],"is_preprint":false},{"year":2018,"finding":"Endothelial cell-derived MIF decreases pericyte contractility by reducing myosin light chain phosphorylation and increases intercellular pericyte gap formation, thereby enhancing neutrophil transmigration; EC-specific MIF knockout mice show decreased neutrophil infiltration to BAL and lung tissue and increased myosin light chain phosphorylation in pericytes in acute lung injury.","method":"EC-specific MIF conditional knockout mice; in vitro microvascular model; myosin light chain phosphorylation Western blot; silicone substrate contractility assay; bronchoalveolar lavage cell counting","journal":"FASEB journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — cell-type-specific KO with defined molecular mechanism and in vivo validation; single lab","pmids":["30252532"],"is_preprint":false},{"year":2009,"finding":"MIF induces MIP-2 accumulation in alveolar macrophages through p44/p42 MAPK activation downstream of CD74; MIF-induced MAPK phosphorylation and MIP-2 release by macrophages are blocked by anti-CD74 antibody.","method":"Macrophage culture; MIF stimulation; anti-CD74 antibody blockade; Western blot for p44/p42 MAPK phosphorylation; ELISA for MIP-2","journal":"Respiratory research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — cell-based signaling with antibody blockade of defined receptor; single lab, mechanistic clarity","pmids":["19413900"],"is_preprint":false},{"year":2016,"finding":"4-IPP (MIF inhibitor) blocks MIF/CD74 internalization, activates JNK, dose-dependently inhibits proliferation, and induces apoptosis and mitotic cell death in thyroid carcinoma cells co-expressing MIF and CD74; effects are partially reduced in CD74-negative cells.","method":"4-IPP pharmacological inhibition; cell viability assay; Western blot for JNK activation; flow cytometry for apoptosis; immunohistochemistry of patient samples","journal":"Endocrine-related cancer","confidence":"Low","confidence_rationale":"Tier 3 / Weak — pharmacological inhibitor with defined receptor co-expression context but relying on a non-specific small molecule; single lab","pmids":["26206776"],"is_preprint":false}],"current_model":"MIF is a constitutively expressed, secreted 12.5 kDa cytokine that signals extracellularly through a primary receptor complex composed of CD74 (high-affinity binding partner, Kd ~9 nM) together with co-receptors CD44 and CXCR4/CXCR2, activating ERK1/2, AKT, p38, and RhoA downstream pathways to drive inflammation, cell proliferation, and survival; intracellularly, MIF functions as a 3' flap nuclease at replication forks (requiring nuclear translocation in S phase), suppresses p53 activity, binds PINK1 to block mitophagy, and its activity is regulated by HDAC6-mediated acetylation at K78 (which prevents MIF–AIF interaction and nuclear translocation); its transcription is driven by HIF-1α through an HRE element and by the transcription factor ICBP90/UHRF1 acting at the polymorphic −794 CATT microsatellite, while glucocorticoids paradoxically induce MIF secretion via GRE/ATF-CRE elements, allowing MIF to counter-regulate glucocorticoid immunosuppression."},"narrative":{"mechanistic_narrative":"MIF is a constitutively expressed, secreted ~12.5 kDa cytokine that drives inflammation, leukocyte recruitment, and cell proliferation/survival by signaling extracellularly through the high-affinity receptor CD74 (Kd ~9 nM), which is required for MIF-induced ERK1/2 activation, proliferation, and PGE2 production [PMID:12782713, PMID:7947826]. At the cell surface CD74 assembles with co-receptors to form functional signaling complexes: CD74/CXCR4 heterocomplexes mediate MIF-specific AKT activation and leukocyte/CD4+ T-cell migration [PMID:19665027, PMID:38992165], while MIF recruits CD44 into a CD74/CD44 complex that drives MAPK and RhoA signaling and an invasive phenotype [PMID:27872288]. Through these receptor complexes MIF activates ERK1/2, p38, AKT, and RhoA in diverse cell types—podocytes, macrophages, microglia, and fibroblasts—to control chemokine output (e.g., MIP-2), TRAIL/MCP-1 induction, macrophage polarization, and adhesion-dependent cyclin D1 expression and DNA synthesis [PMID:19413900, PMID:18842989, PMID:27157615, PMID:12297513]. MIF also functions independently of CD74 as an autocrine growth factor, suppressing the Rb/E2F and p53 tumor-suppressor axes: loss of MIF (together with its homolog D-DT) restores p53 phosphorylation and activity via ROS-driven AMPK activation, and MIF loss delays Myc-induced lymphomagenesis by perturbing E2F and enhancing p53 function [PMID:12297513, PMID:24932684, PMID:15947793]. Intracellularly, MIF acts as a 3' flap nuclease that translocates to the nucleus in S phase and co-localizes with PARP1 at replication forks to resolve replication stress, with nuclease-dead MIF failing to rescue DNA synthesis defects [PMID:34012010]. MIF activity is set by post-translational modification: HDAC6 deacetylates MIF at K78 to permit MIF–AIF interaction and nuclear translocation in ischemic neurons [PMID:35585040], and C-terminal O-GlcNAcylation directs a secreted MIF pool that binds EGFR to antagonize EGF signaling [PMID:26280537]. MIF additionally binds PINK1 to block PINK1–Parkin coupling and mitophagy [PMID:38956064] and is the first identified endogenous inhibitor of the serine protease HTRA1 [PMID:28726057]. MIF transcription is controlled by ICBP90/UHRF1 acting at the polymorphic −794 CATT microsatellite [PMID:26752645], by HIF-1α through a hypoxia response element [PMID:16854377], and by the nuclear receptor RORα [PMID:27925372].","teleology":[{"year":1994,"claim":"Established MIF as a defined, bioactive protein rather than a crude activity, anchoring all subsequent mechanism: recombinant MIF is a 12.5 kDa, structured protein with intrinsic immunoregulatory function.","evidence":"Recombinant human/mouse MIF expression, mass spectrometry, circular dichroism, and bioactivity assays (migration inhibition, TNF-α, nitric oxide)","pmids":["7947826"],"confidence":"High","gaps":["No receptor or signaling mechanism identified","Secretion route and structural basis of activity not defined"]},{"year":2002,"claim":"Showed MIF is a secreted autocrine mediator of growth signaling, linking it to cell-cycle control via the Rb/E2F axis before its receptor was known.","evidence":"MIF-null mouse fibroblasts with recombinant reconstitution, PKC inhibition, cyclin D1 reporter, Rb/E2F activity assays","pmids":["12297513"],"confidence":"Medium","gaps":["Receptor mediating autocrine MIF action not identified here","Mechanism connecting secreted MIF to Rb/E2F not resolved"]},{"year":2003,"claim":"Identified the high-affinity MIF receptor, converting MIF from an orphan cytokine into a defined receptor-ligand signaling system.","evidence":"Expression cloning, surface plasmon resonance binding (Kd ~9 nM), and CD74-dependent ERK1/2 / proliferation / PGE2 assays","pmids":["12782713"],"confidence":"High","gaps":["CD74 lacks an intracellular signaling domain — co-receptor requirement unaddressed","Quantitative contribution of CD74 vs other binding partners not resolved"]},{"year":2005,"claim":"Demonstrated in vivo that MIF promotes tumorigenesis through tumor-suppressor circuits, establishing the E2F/p53 axis as a key MIF effector pathway.","evidence":"Eμ-Myc lymphoma model on MIF-null background, E2F DNA-binding and p53 pathway assays, tumor onset kinetics","pmids":["15947793"],"confidence":"Medium","gaps":["Molecular link between MIF and E2F/p53 regulation not mechanistically defined","Does not distinguish secreted vs intracellular MIF activity"]},{"year":2006,"claim":"Defined transcriptional control of MIF under hypoxia, explaining inducible MIF expression in low-oxygen tissue contexts.","evidence":"HIF-1α overexpression, HRE reporter and promoter deletion assays, CREB modulation","pmids":["16854377"],"confidence":"Medium","gaps":["Relative contribution of HIF-1α vs other promoter elements in vivo not quantified"]},{"year":2009,"claim":"Resolved the co-receptor problem by showing CD74 partners with CXCR4 (and engages p44/p42 MAPK in macrophages), explaining how the signaling-incompetent CD74 transduces MIF signals to AKT and chemokine output.","evidence":"Co-IP of endogenous CD74/CXCR4, AMD3100/antibody blockade, AKT phosphorylation, and in vivo MIF-induced alveolar neutrophil/MIP-2 assays","pmids":["19665027","19413900","19726058"],"confidence":"Medium","gaps":["Stoichiometry of the CD74/CXCR4 complex not defined","Autocrine MIF growth role in pancreatic cancer rests on single-method knockdown"]},{"year":2014,"claim":"Showed MIF and its homolog D-DT cooperatively suppress p53, providing a mechanistic basis for MIF's oncogenic survival function via ROS/AMPK.","evidence":"Dual siRNA knockdown of MIF and D-DT, p53 phosphorylation Western blots, ROS measurement, AMPK inhibitor experiments, transformation assays","pmids":["24932684"],"confidence":"Medium","gaps":["Direct biochemical target of MIF/D-DT upstream of ROS not identified","Functional redundancy boundaries between MIF and D-DT unresolved"]},{"year":2015,"claim":"Identified a C-terminal O-GlcNAcylation that diverts secreted MIF to antagonize EGFR, revealing PTM-gated functional specialization of MIF pools.","evidence":"Mass spectrometry PTM mapping, Ser112/Thr113 mutagenesis, MIF-EGFR binding, invasion/proliferation/tumor assays, MMP13 secretion","pmids":["26280537"],"confidence":"High","gaps":["Enzyme adding the O-GlcNAc and its regulation not defined","Balance between EGFR-antagonist and CD74-agonist MIF pools in vivo unknown"]},{"year":2016,"claim":"Expanded the receptor repertoire (CD44) and identified the dominant transcriptional driver ICBP90/UHRF1 at the disease-associated −794 CATT microsatellite, plus RORα as a direct regulator, connecting MIF genetics to expression.","evidence":"Co-IP of CD74/CD44, RhoA and invasion assays; affinity chromatography + LC-MS/MS and shRNA for ICBP90; ChIP and ligand assays for RORα; microglial signaling assays","pmids":["27872288","26752645","27925372","27157615"],"confidence":"High","gaps":["Interplay among CD74/CXCR4/CD44 receptor configurations not unified","How CATT repeat length mechanistically alters ICBP90 binding not resolved"]},{"year":2017,"claim":"Identified MIF as the first endogenous HTRA1 inhibitor, adding a protease-regulatory function distinct from cytokine signaling.","evidence":"Co-IP, in vitro protease inhibition assay, astrocyte co-localization by immunohistochemistry","pmids":["28726057"],"confidence":"Medium","gaps":["Structural basis of MIF–HTRA1 inhibition not determined","Physiological consequences of the interaction not established in vivo"]},{"year":2018,"claim":"Defined cell-type-specific and context-dependent MIF signaling outputs—endothelial MIF relaxing pericytes for neutrophil transit, and soluble CD74 rerouting MIF/CXCR4 survival signaling to necroptosis.","evidence":"EC-specific MIF conditional KO with myosin light chain phosphorylation and BAL counts; sCD74+MIF co-treatment of cardiac fibroblasts with RIP1/RIP3 inhibitors and gene profiling","pmids":["30252532","30371153"],"confidence":"Medium","gaps":["Mechanism by which sCD74 switches AKT survival to RIP1/RIP3 death not defined","Receptor configuration for endothelial MIF effect on pericytes not mapped"]},{"year":2021,"claim":"Revealed an intracellular enzymatic function—MIF is a 3' flap nuclease acting at replication forks—establishing a moonlighting role wholly distinct from cytokine signaling.","evidence":"In vitro nuclease assay, nuclear fractionation, PARP1 co-localization, and nuclease-dead mutant rescue in MIF-knockdown cancer cells","pmids":["34012010"],"confidence":"High","gaps":["Trigger for S-phase nuclear translocation not defined","Relationship between nuclease and cytokine functions of the same protein unresolved"]},{"year":2022,"claim":"Showed that K78 acetylation status, controlled by HDAC6, gates MIF–AIF binding and nuclear translocation, providing a switch governing MIF's intracellular pro-death function.","evidence":"Mass spectrometry K78 acetylation mapping, MIF-AIF co-IP, K78Q knock-in mice, HDAC6 ablation/inhibition, nuclear fractionation in ischemic neurons","pmids":["35585040"],"confidence":"High","gaps":["Acetyltransferase opposing HDAC6 not identified","Link between K78-controlled AIF binding and the flap-nuclease function not integrated"]},{"year":2024,"claim":"Added a mitochondrial quality-control role: MIF binds PINK1 to block PINK1–Parkin coupling and mitophagy, expanding MIF's intracellular interactome and cell-death control.","evidence":"MIF-PINK1 co-IP, ISO-1 inhibition and overexpression, mitophagy flux and apoptosis assays in renal tubular cells; PLA visualization of CD74/CXCR4 on CD4+ T cells","pmids":["38956064","38992165"],"confidence":"Medium","gaps":["Whether PINK1 binding requires specific MIF PTMs or localization not addressed","Direct vs indirect mechanism of PINK1–Parkin disruption not resolved"]},{"year":null,"claim":"How a single small protein partitions between secreted cytokine, intracellular flap nuclease, protease inhibitor, and mitophagy regulator—and how PTMs (O-GlcNAc, K78 acetylation) coordinate these fates—remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified model linking MIF's enzymatic and signaling functions","No structural framework integrating receptor binding, nuclease activity, and protein-interaction surfaces","Tissue-level balance of pro- vs anti-tumor and pro- vs anti-survival MIF activities undefined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140097","term_label":"catalytic activity, acting on DNA","supporting_discovery_ids":[9]},{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[0,1,2,5]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[13,15]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[0,2]}],"localization":[{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[0,1,7,8]},{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[9,14]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[14,15]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[0,1,3,6,23]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,2,4,5]},{"term_id":"R-HSA-73894","term_label":"DNA Repair","supporting_discovery_ids":[9]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[14,15]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[10,11,16]}],"complexes":["CD74/CXCR4 receptor complex","CD74/CD44 receptor complex"],"partners":["CD74","CXCR4","CD44","PARP1","EGFR","HTRA1","PINK1","AIF"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P03971","full_name":"Anti-Muellerian hormone","aliases":["Muellerian-inhibiting factor","Muellerian-inhibiting substance","MIS"],"length_aa":560,"mass_kda":59.2,"function":"The anti-Muellerian hormone (AMH) plays an important role in several reproductive functions (PubMed:14742691, PubMed:34155118, PubMed:3754790, PubMed:8469238). Anti-Muellerian hormone binds and activates AMHR2, its specific type-II receptor, that heterodimerizes with type-I receptors (ACVR1 and BMPR1A) to regulate target gene expression through downstream SMAD protein signal transduction (PubMed:20861221, PubMed:34155118). Produced and secreted by Sertoli cells of the male fetus, anti-Muellerian hormone induces Muellerian duct regression during male fetal sexual differentiation (PubMed:34155118, PubMed:3754790, PubMed:8469238). In female, it is produced by granulosa cells of the preantral and small antral follicles and acts as a negative regulator of the primordial to primary follicle transition and decreases FSH sensitivity of growing follicles (PubMed:14742691). Also plays a role in Leydig cell differentiation and function (By similarity)","subcellular_location":"Secreted","url":"https://www.uniprot.org/uniprotkb/P03971/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/MIF","classification":"Not Classified","n_dependent_lines":5,"n_total_lines":1208,"dependency_fraction":0.0041390728476821195},"opencell":{"profiled":true,"resolved_as":"","ensg_id":"ENSG00000240972","cell_line_id":"CID000997","localizations":[{"compartment":"cytoplasmic","grade":3},{"compartment":"nucleoplasm","grade":3}],"interactors":[{"gene":"CSNK2A1;CSNK2A3","stoichiometry":10.0},{"gene":"RBM14","stoichiometry":10.0},{"gene":"RAB2A","stoichiometry":10.0},{"gene":"PSME3","stoichiometry":10.0},{"gene":"DDB1","stoichiometry":4.0},{"gene":"RAB1B;RAB1C","stoichiometry":4.0},{"gene":"TMED10","stoichiometry":4.0},{"gene":"RABAC1","stoichiometry":4.0},{"gene":"CEP85","stoichiometry":0.2},{"gene":"FIGNL1","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/target/CID000997","total_profiled":1310},"omim":[{"mim_id":"613005","title":"SANTOS SYNDROME","url":"https://www.omim.org/entry/613005"},{"mim_id":"611275","title":"BCL2/ADENOVIRUS E1B 19-KD PROTEIN-INTERACTING PROTEIN 2-LIKE; BNIPL","url":"https://www.omim.org/entry/611275"},{"mim_id":"610379","title":"WEST NILE VIRUS, SUSCEPTIBILITY TO","url":"https://www.omim.org/entry/610379"},{"mim_id":"610182","title":"PALMDELPHIN; PALMD","url":"https://www.omim.org/entry/610182"},{"mim_id":"604850","title":"COP9 SIGNALOSOME, SUBUNIT 5; COPS5","url":"https://www.omim.org/entry/604850"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Enhanced","locations":[{"location":"Cytosol","reliability":"Enhanced"},{"location":"Nucleoplasm","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/MIF"},"hgnc":{"alias_symbol":["GIF"],"prev_symbol":["GLIF"]},"alphafold":{"accession":"P03971","domains":[{"cath_id":"-","chopping":"55-254","consensus_level":"high","plddt":81.351,"start":55,"end":254},{"cath_id":"2.10.90.10","chopping":"457-560","consensus_level":"high","plddt":78.734,"start":457,"end":560}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P03971","model_url":"https://alphafold.ebi.ac.uk/files/AF-P03971-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P03971-F1-predicted_aligned_error_v6.png","plddt_mean":68.62},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=MIF","jax_strain_url":"https://www.jax.org/strain/search?query=MIF"},"sequence":{"accession":"P03971","fasta_url":"https://rest.uniprot.org/uniprotkb/P03971.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P03971/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P03971"}},"corpus_meta":[{"pmid":"12782713","id":"PMC_12782713","title":"MIF signal transduction initiated by binding to CD74.","date":"2003","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/12782713","citation_count":941,"is_preprint":false},{"pmid":"7947826","id":"PMC_7947826","title":"Purification, bioactivity, and secondary structure analysis of mouse and human macrophage migration inhibitory factor (MIF).","date":"1994","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/7947826","citation_count":378,"is_preprint":false},{"pmid":"34673115","id":"PMC_34673115","title":"Macrophage migration inhibitory factor (MIF): A multifaceted cytokine regulated by genetic and physiological strategies.","date":"2021","source":"Pharmacology & therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/34673115","citation_count":240,"is_preprint":false},{"pmid":"31197253","id":"PMC_31197253","title":"The immunobiology of MIF: function, genetics and prospects for precision medicine.","date":"2019","source":"Nature reviews. Rheumatology","url":"https://pubmed.ncbi.nlm.nih.gov/31197253","citation_count":217,"is_preprint":false},{"pmid":"30682543","id":"PMC_30682543","title":"Evolving complexity of MIF signaling.","date":"2019","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/30682543","citation_count":204,"is_preprint":false},{"pmid":"19665027","id":"PMC_19665027","title":"A functional heteromeric MIF receptor formed by CD74 and CXCR4.","date":"2009","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/19665027","citation_count":202,"is_preprint":false},{"pmid":"20520854","id":"PMC_20520854","title":"Macrophage migration inhibitory factor (MIF): a promising biomarker.","date":"2010","source":"Drug news & perspectives","url":"https://pubmed.ncbi.nlm.nih.gov/20520854","citation_count":199,"is_preprint":false},{"pmid":"11032394","id":"PMC_11032394","title":"Macrophage migration inhibitory factor (MIF): its essential role in the immune system and cell growth.","date":"2000","source":"Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research","url":"https://pubmed.ncbi.nlm.nih.gov/11032394","citation_count":176,"is_preprint":false},{"pmid":"22507380","id":"PMC_22507380","title":"D-dopachrome tautomerase (D-DT or MIF-2): doubling the MIF cytokine family.","date":"2012","source":"Cytokine","url":"https://pubmed.ncbi.nlm.nih.gov/22507380","citation_count":150,"is_preprint":false},{"pmid":"9034724","id":"PMC_9034724","title":"Macrophage migration inhibitory factor (MIF): a glucocorticoid counter-regulator within the immune system.","date":"1997","source":"Critical reviews in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/9034724","citation_count":143,"is_preprint":false},{"pmid":"33324425","id":"PMC_33324425","title":"MIF-Dependent Control of Tumor Immunity.","date":"2020","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/33324425","citation_count":142,"is_preprint":false},{"pmid":"26777977","id":"PMC_26777977","title":"Targeting MIF in Cancer: Therapeutic Strategies, Current Developments, and Future Opportunities.","date":"2016","source":"Medicinal research reviews","url":"https://pubmed.ncbi.nlm.nih.gov/26777977","citation_count":139,"is_preprint":false},{"pmid":"31414920","id":"PMC_31414920","title":"Macrophage migration inhibitory factor (MIF) as a therapeutic target for rheumatoid arthritis and systemic lupus erythematosus.","date":"2019","source":"Expert opinion on therapeutic targets","url":"https://pubmed.ncbi.nlm.nih.gov/31414920","citation_count":130,"is_preprint":false},{"pmid":"9606175","id":"PMC_9606175","title":"MIF expression in the rat brain: implications for neuronal function.","date":"1998","source":"Molecular medicine (Cambridge, Mass.)","url":"https://pubmed.ncbi.nlm.nih.gov/9606175","citation_count":128,"is_preprint":false},{"pmid":"27157615","id":"PMC_27157615","title":"MIF-CD74 signaling impedes microglial M1 polarization and facilitates brain tumorigenesis.","date":"2016","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/27157615","citation_count":117,"is_preprint":false},{"pmid":"14607271","id":"PMC_14607271","title":"Mechanisms and effectors of MIF-dependent promotion of tumourigenesis.","date":"2004","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/14607271","citation_count":113,"is_preprint":false},{"pmid":"16854377","id":"PMC_16854377","title":"Dual regulation of macrophage migration inhibitory factor (MIF) expression in hypoxia by CREB and HIF-1.","date":"2006","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/16854377","citation_count":110,"is_preprint":false},{"pmid":"18791328","id":"PMC_18791328","title":"Role of MIF in inflammation and tumorigenesis.","date":"2008","source":"Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/18791328","citation_count":109,"is_preprint":false},{"pmid":"31960418","id":"PMC_31960418","title":"Exosomes from mesenchymal stem cells overexpressing MIF enhance myocardial repair.","date":"2020","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/31960418","citation_count":109,"is_preprint":false},{"pmid":"26119751","id":"PMC_26119751","title":"A Secreted MIF Cytokine Enables Aphid Feeding and Represses Plant Immune Responses.","date":"2015","source":"Current biology : CB","url":"https://pubmed.ncbi.nlm.nih.gov/26119751","citation_count":105,"is_preprint":false},{"pmid":"19413900","id":"PMC_19413900","title":"Macrophage CD74 contributes to MIF-induced pulmonary inflammation.","date":"2009","source":"Respiratory research","url":"https://pubmed.ncbi.nlm.nih.gov/19413900","citation_count":104,"is_preprint":false},{"pmid":"18842989","id":"PMC_18842989","title":"The MIF receptor CD74 in diabetic podocyte injury.","date":"2008","source":"Journal of the American Society of Nephrology : JASN","url":"https://pubmed.ncbi.nlm.nih.gov/18842989","citation_count":101,"is_preprint":false},{"pmid":"30914802","id":"PMC_30914802","title":"MIF family proteins in genitourinary cancer: tumorigenic roles and therapeutic potential.","date":"2019","source":"Nature reviews. Urology","url":"https://pubmed.ncbi.nlm.nih.gov/30914802","citation_count":95,"is_preprint":false},{"pmid":"10564712","id":"PMC_10564712","title":"Enhancement of macrophage migration inhibitory factor (MIF) expression in injured epidermis and cultured fibroblasts.","date":"2000","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/10564712","citation_count":95,"is_preprint":false},{"pmid":"22454509","id":"PMC_22454509","title":"Macrophage migration inhibitory factor (MIF) promotes cell survival and proliferation of neural stem/progenitor cells.","date":"2012","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/22454509","citation_count":92,"is_preprint":false},{"pmid":"7706726","id":"PMC_7706726","title":"Cloning and characterization of the gene for mouse macrophage migration inhibitory factor (MIF).","date":"1995","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/7706726","citation_count":92,"is_preprint":false},{"pmid":"23329140","id":"PMC_23329140","title":"The vascular biology of macrophage migration inhibitory factor (MIF). Expression and effects in inflammation, atherogenesis and angiogenesis.","date":"2013","source":"Thrombosis and haemostasis","url":"https://pubmed.ncbi.nlm.nih.gov/23329140","citation_count":84,"is_preprint":false},{"pmid":"27872094","id":"PMC_27872094","title":"MIF-Induced Stromal PKCβ/IL8 Is Essential in Human Acute Myeloid Leukemia.","date":"2016","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/27872094","citation_count":79,"is_preprint":false},{"pmid":"27872288","id":"PMC_27872288","title":"MIF allele-dependent regulation of the MIF coreceptor CD44 and role in rheumatoid arthritis.","date":"2016","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/27872288","citation_count":75,"is_preprint":false},{"pmid":"30962001","id":"PMC_30962001","title":"Rediscovering MIF: New Tricks for an Old Cytokine.","date":"2019","source":"Trends in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/30962001","citation_count":74,"is_preprint":false},{"pmid":"22110378","id":"PMC_22110378","title":"Macrophage migration inhibitory factor (MIF): a key player in protozoan infections.","date":"2011","source":"International journal of biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/22110378","citation_count":74,"is_preprint":false},{"pmid":"15659324","id":"PMC_15659324","title":"Role of macrophage migration inhibitory factor (MIF) in the skin.","date":"2005","source":"Journal of dermatological science","url":"https://pubmed.ncbi.nlm.nih.gov/15659324","citation_count":68,"is_preprint":false},{"pmid":"21158933","id":"PMC_21158933","title":"MIF: a key player in cutaneous biology and wound healing.","date":"2011","source":"Experimental dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/21158933","citation_count":65,"is_preprint":false},{"pmid":"22968741","id":"PMC_22968741","title":"MIF, MIF alleles, and prospects for therapeutic intervention in autoimmunity.","date":"2012","source":"Journal of clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/22968741","citation_count":64,"is_preprint":false},{"pmid":"22959722","id":"PMC_22959722","title":"MIF, CD74 and other partners in kidney disease: tales of a promiscuous couple.","date":"2012","source":"Cytokine & growth factor reviews","url":"https://pubmed.ncbi.nlm.nih.gov/22959722","citation_count":64,"is_preprint":false},{"pmid":"18385967","id":"PMC_18385967","title":"Chemokine-like functions of MIF in atherosclerosis.","date":"2008","source":"Journal of molecular medicine (Berlin, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/18385967","citation_count":62,"is_preprint":false},{"pmid":"16474429","id":"PMC_16474429","title":"Insight into the biology of macrophage migration inhibitory factor (MIF) revealed by the cloning of its cell surface receptor.","date":"2006","source":"Cell research","url":"https://pubmed.ncbi.nlm.nih.gov/16474429","citation_count":62,"is_preprint":false},{"pmid":"26617609","id":"PMC_26617609","title":"MIF: Implications in the Pathoetiology of Systemic Lupus Erythematosus.","date":"2015","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/26617609","citation_count":61,"is_preprint":false},{"pmid":"29773026","id":"PMC_29773026","title":"Macrophage Migration Inhibitory Factor (MIF): A Glucocorticoid Counter-Regulator within the Immune System.","date":"2017","source":"Critical reviews in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/29773026","citation_count":56,"is_preprint":false},{"pmid":"31013837","id":"PMC_31013837","title":"Role of Macrophage Migration Inhibitory Factor (MIF) in Melanoma.","date":"2019","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/31013837","citation_count":56,"is_preprint":false},{"pmid":"26280537","id":"PMC_26280537","title":"Secreted and O-GlcNAcylated MIF binds to the human EGF receptor and inhibits its activation.","date":"2015","source":"Nature cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/26280537","citation_count":56,"is_preprint":false},{"pmid":"30371153","id":"PMC_30371153","title":"Soluble CD74 Reroutes MIF/CXCR4/AKT-Mediated Survival of Cardiac Myofibroblasts to Necroptosis.","date":"2018","source":"Journal of the American Heart Association","url":"https://pubmed.ncbi.nlm.nih.gov/30371153","citation_count":54,"is_preprint":false},{"pmid":"26752645","id":"PMC_26752645","title":"Transcription factor ICBP90 regulates the MIF promoter and immune susceptibility locus.","date":"2016","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/26752645","citation_count":54,"is_preprint":false},{"pmid":"11488984","id":"PMC_11488984","title":"Neuroendocrine properties of macrophage migration inhibitory factor (MIF).","date":"2001","source":"Immunology and cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/11488984","citation_count":52,"is_preprint":false},{"pmid":"26257740","id":"PMC_26257740","title":"MIF and CXCL12 in Cardiovascular Diseases: Functional Differences and Similarities.","date":"2015","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/26257740","citation_count":50,"is_preprint":false},{"pmid":"28114961","id":"PMC_28114961","title":"MIF/CD74 axis is a target for novel therapies in colon carcinomatosis.","date":"2017","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/28114961","citation_count":49,"is_preprint":false},{"pmid":"11753217","id":"PMC_11753217","title":"Macrophage migration inhibitory factor (MIF) modulates innate immune responses induced by endotoxin and Gram-negative bacteria.","date":"2001","source":"Journal of endotoxin research","url":"https://pubmed.ncbi.nlm.nih.gov/11753217","citation_count":49,"is_preprint":false},{"pmid":"16522371","id":"PMC_16522371","title":"Tumor-derived macrophage migration inhibitory factor (MIF) inhibits T lymphocyte activation.","date":"2006","source":"Cytokine","url":"https://pubmed.ncbi.nlm.nih.gov/16522371","citation_count":48,"is_preprint":false},{"pmid":"12297513","id":"PMC_12297513","title":"Adhesion-dependent signaling by macrophage migration inhibitory factor (MIF).","date":"2002","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12297513","citation_count":47,"is_preprint":false},{"pmid":"38992165","id":"PMC_38992165","title":"CD74 is a functional MIF receptor on activated CD4+ T cells.","date":"2024","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/38992165","citation_count":46,"is_preprint":false},{"pmid":"27780588","id":"PMC_27780588","title":"The non-mammalian MIF superfamily.","date":"2016","source":"Immunobiology","url":"https://pubmed.ncbi.nlm.nih.gov/27780588","citation_count":46,"is_preprint":false},{"pmid":"19726058","id":"PMC_19726058","title":"Inhibition of MIF leads to cell cycle arrest and apoptosis in pancreatic cancer cells.","date":"2009","source":"The Journal of surgical research","url":"https://pubmed.ncbi.nlm.nih.gov/19726058","citation_count":46,"is_preprint":false},{"pmid":"30680604","id":"PMC_30680604","title":"The Role of MIF on Eosinophil Biology and Eosinophilic Inflammation.","date":"2020","source":"Clinical reviews in allergy & immunology","url":"https://pubmed.ncbi.nlm.nih.gov/30680604","citation_count":45,"is_preprint":false},{"pmid":"24683185","id":"PMC_24683185","title":"HLA-DRα1 constructs block CD74 expression and MIF effects in experimental autoimmune encephalomyelitis.","date":"2014","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/24683185","citation_count":44,"is_preprint":false},{"pmid":"23044992","id":"PMC_23044992","title":"Deletion of CD74, a putative MIF receptor, in mice enhances osteoclastogenesis and decreases bone mass.","date":"2013","source":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","url":"https://pubmed.ncbi.nlm.nih.gov/23044992","citation_count":41,"is_preprint":false},{"pmid":"25255103","id":"PMC_25255103","title":"MIF contributes to Trypanosoma brucei associated immunopathogenicity development.","date":"2014","source":"PLoS pathogens","url":"https://pubmed.ncbi.nlm.nih.gov/25255103","citation_count":40,"is_preprint":false},{"pmid":"24932684","id":"PMC_24932684","title":"MIF family members cooperatively inhibit p53 expression and activity.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24932684","citation_count":39,"is_preprint":false},{"pmid":"26851955","id":"PMC_26851955","title":"Predicted structure of MIF/CD74 and RTL1000/CD74 complexes.","date":"2016","source":"Metabolic brain disease","url":"https://pubmed.ncbi.nlm.nih.gov/26851955","citation_count":37,"is_preprint":false},{"pmid":"34012010","id":"PMC_34012010","title":"MIF is a 3' flap nuclease that facilitates DNA replication and promotes tumor growth.","date":"2021","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/34012010","citation_count":35,"is_preprint":false},{"pmid":"21977228","id":"PMC_21977228","title":"MIF participates in Toxoplasma gondii-induced pathology following oral infection.","date":"2011","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/21977228","citation_count":35,"is_preprint":false},{"pmid":"25643609","id":"PMC_25643609","title":"MIF and CD74 - suitability as clinical biomarkers.","date":"2014","source":"Mini reviews in medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25643609","citation_count":34,"is_preprint":false},{"pmid":"32208924","id":"PMC_32208924","title":"The role of MIF in chronic lung diseases: looking beyond inflammation.","date":"2020","source":"American journal of physiology. Lung cellular and molecular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/32208924","citation_count":34,"is_preprint":false},{"pmid":"11723699","id":"PMC_11723699","title":"Sharable representation of clinical guidelines in GLIF: relationship to the Arden Syntax.","date":"2001","source":"Journal of biomedical informatics","url":"https://pubmed.ncbi.nlm.nih.gov/11723699","citation_count":34,"is_preprint":false},{"pmid":"27955690","id":"PMC_27955690","title":"CHD7 promotes proliferation of neural stem cells mediated by MIF.","date":"2016","source":"Molecular brain","url":"https://pubmed.ncbi.nlm.nih.gov/27955690","citation_count":34,"is_preprint":false},{"pmid":"36657717","id":"PMC_36657717","title":"Obacunone targets macrophage migration inhibitory factor (MIF) to impede osteoclastogenesis and alleviate ovariectomy-induced bone loss.","date":"2023","source":"Journal of advanced research","url":"https://pubmed.ncbi.nlm.nih.gov/36657717","citation_count":33,"is_preprint":false},{"pmid":"30252532","id":"PMC_30252532","title":"Endothelial cell-secreted MIF reduces pericyte contractility and enhances neutrophil extravasation.","date":"2018","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/30252532","citation_count":32,"is_preprint":false},{"pmid":"15947793","id":"PMC_15947793","title":"MIF loss impairs Myc-induced lymphomagenesis.","date":"2005","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/15947793","citation_count":32,"is_preprint":false},{"pmid":"19646897","id":"PMC_19646897","title":"Glucocorticoid-induced MIF expression by human CEM T cells.","date":"2009","source":"Cytokine","url":"https://pubmed.ncbi.nlm.nih.gov/19646897","citation_count":31,"is_preprint":false},{"pmid":"30333830","id":"PMC_30333830","title":"Macrophage Migration Inhibitory Factor (MIF) Drives Murine Psoriasiform Dermatitis.","date":"2018","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/30333830","citation_count":29,"is_preprint":false},{"pmid":"17988762","id":"PMC_17988762","title":"From MIF-1 to endomorphin: the Tyr-MIF-1 family of peptides.","date":"2007","source":"Peptides","url":"https://pubmed.ncbi.nlm.nih.gov/17988762","citation_count":29,"is_preprint":false},{"pmid":"26206776","id":"PMC_26206776","title":"4-IPP, a selective MIF inhibitor, causes mitotic catastrophe in thyroid carcinomas.","date":"2015","source":"Endocrine-related cancer","url":"https://pubmed.ncbi.nlm.nih.gov/26206776","citation_count":29,"is_preprint":false},{"pmid":"30678084","id":"PMC_30678084","title":"Macrophage Migration Inhibitory Factor (MIF) Expression Increases during Myocardial Infarction and Supports Pro-Inflammatory Signaling in Cardiac Fibroblasts.","date":"2019","source":"Biomolecules","url":"https://pubmed.ncbi.nlm.nih.gov/30678084","citation_count":28,"is_preprint":false},{"pmid":"34535196","id":"PMC_34535196","title":"Isopsoralen ameliorates rheumatoid arthritis by targeting MIF.","date":"2021","source":"Arthritis research & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/34535196","citation_count":28,"is_preprint":false},{"pmid":"31961019","id":"PMC_31961019","title":"Differential regulation of macrophage activation by the MIF cytokine superfamily members MIF and MIF-2 in adipose tissue during endotoxemia.","date":"2020","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/31961019","citation_count":28,"is_preprint":false},{"pmid":"37520719","id":"PMC_37520719","title":"MIF is a critical regulator of mononuclear phagocytic infiltration in hepatocellular carcinoma.","date":"2023","source":"iScience","url":"https://pubmed.ncbi.nlm.nih.gov/37520719","citation_count":27,"is_preprint":false},{"pmid":"35288645","id":"PMC_35288645","title":"The IL-25-dependent tuft cell circuit driven by intestinal helminths requires macrophage migration inhibitory factor (MIF).","date":"2022","source":"Mucosal immunology","url":"https://pubmed.ncbi.nlm.nih.gov/35288645","citation_count":27,"is_preprint":false},{"pmid":"17640378","id":"PMC_17640378","title":"MIF coordinates the cell cycle with DNA damage checkpoints. Lessons from knockout mouse models.","date":"2007","source":"Cell division","url":"https://pubmed.ncbi.nlm.nih.gov/17640378","citation_count":26,"is_preprint":false},{"pmid":"35585040","id":"PMC_35585040","title":"Macrophage migration inhibitory factor (MIF) acetylation protects neurons from ischemic injury.","date":"2022","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/35585040","citation_count":25,"is_preprint":false},{"pmid":"30667094","id":"PMC_30667094","title":"MIF promotes perineural invasion through EMT in salivary adenoid cystic carcinoma.","date":"2019","source":"Molecular carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/30667094","citation_count":25,"is_preprint":false},{"pmid":"38956064","id":"PMC_38956064","title":"Macrophage migration inhibitory factor (MIF) suppresses mitophagy through disturbing the protein interaction of PINK1-Parkin in sepsis-associated acute kidney injury.","date":"2024","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/38956064","citation_count":24,"is_preprint":false},{"pmid":"34389619","id":"PMC_34389619","title":"Recombinant Mycobacterium smegmatis delivering a fusion protein of human macrophage migration inhibitory factor (MIF) and IL-7 exerts an anticancer effect by inducing an immune response against MIF in a tumor-bearing mouse model.","date":"2021","source":"Journal for immunotherapy of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/34389619","citation_count":24,"is_preprint":false},{"pmid":"28726057","id":"PMC_28726057","title":"Macrophage migration inhibitory factor (MIF) modulates trophic signaling through interaction with serine protease HTRA1.","date":"2017","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/28726057","citation_count":23,"is_preprint":false},{"pmid":"29723777","id":"PMC_29723777","title":"Circulating macrophage migration inhibitory factor (MIF) in patients with heart failure.","date":"2018","source":"Cytokine","url":"https://pubmed.ncbi.nlm.nih.gov/29723777","citation_count":23,"is_preprint":false},{"pmid":"28208600","id":"PMC_28208600","title":"Invariant Chain Complexes and Clusters as Platforms for MIF Signaling.","date":"2017","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/28208600","citation_count":22,"is_preprint":false},{"pmid":"29543531","id":"PMC_29543531","title":"Mif-deficiency favors an atheroprotective autoantibody phenotype in atherosclerosis.","date":"2018","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/29543531","citation_count":22,"is_preprint":false},{"pmid":"10702866","id":"PMC_10702866","title":"Macrophage migration inhibitory factor (MIF) as a paracrine mediator in the interaction of testicular somatic cells.","date":"2000","source":"Andrologia","url":"https://pubmed.ncbi.nlm.nih.gov/10702866","citation_count":22,"is_preprint":false},{"pmid":"32417648","id":"PMC_32417648","title":"Immune modulation by the macrophage migration inhibitory factor (MIF) family: D-dopachrome tautomerase (DDT) is not (always) a backup system.","date":"2020","source":"Cytokine","url":"https://pubmed.ncbi.nlm.nih.gov/32417648","citation_count":22,"is_preprint":false},{"pmid":"28912189","id":"PMC_28912189","title":"Associations between circulating macrophage migration inhibitory factor (MIF) levels and rheumatoid arthritis, and between MIF gene polymorphisms and disease susceptibility: a meta-analysis.","date":"2017","source":"Postgraduate medical journal","url":"https://pubmed.ncbi.nlm.nih.gov/28912189","citation_count":21,"is_preprint":false},{"pmid":"33823474","id":"PMC_33823474","title":"Macrophage migration inhibitory factor (MIF) enhances hypochlorous acid production in phagocytic neutrophils.","date":"2021","source":"Redox biology","url":"https://pubmed.ncbi.nlm.nih.gov/33823474","citation_count":21,"is_preprint":false},{"pmid":"22085783","id":"PMC_22085783","title":"MIF from mussel: coding sequence, phylogeny, polymorphism, 3D model and regulation of expression.","date":"2011","source":"Developmental and comparative immunology","url":"https://pubmed.ncbi.nlm.nih.gov/22085783","citation_count":20,"is_preprint":false},{"pmid":"2893356","id":"PMC_2893356","title":"MIF-1 and Tyr-MIF-1 augment GABA-stimulated benzodiazepine receptor binding.","date":"1987","source":"Peptides","url":"https://pubmed.ncbi.nlm.nih.gov/2893356","citation_count":19,"is_preprint":false},{"pmid":"9629239","id":"PMC_9629239","title":"Neuroimmunomodulation by macrophage migration inhibitory factor (MIF).","date":"1998","source":"Annals of the New York Academy of Sciences","url":"https://pubmed.ncbi.nlm.nih.gov/9629239","citation_count":19,"is_preprint":false},{"pmid":"7907473","id":"PMC_7907473","title":"Differential metabolism of Tyr-MIF-1 and MIF-1 in rat and human plasma.","date":"1994","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/7907473","citation_count":19,"is_preprint":false},{"pmid":"38548489","id":"PMC_38548489","title":"Macrophage migration inhibitor factor (MIF): Potential role in cognitive impairment disorders.","date":"2024","source":"Cytokine & growth factor reviews","url":"https://pubmed.ncbi.nlm.nih.gov/38548489","citation_count":18,"is_preprint":false},{"pmid":"25277536","id":"PMC_25277536","title":"Stromal-dependent tumor promotion by MIF family members.","date":"2014","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/25277536","citation_count":17,"is_preprint":false},{"pmid":"27925372","id":"PMC_27925372","title":"CYP19A1, MIF and ABCA1 genes are targets of the RORα in monocyte and endothelial cells.","date":"2017","source":"Cell biology international","url":"https://pubmed.ncbi.nlm.nih.gov/27925372","citation_count":17,"is_preprint":false},{"pmid":"16728343","id":"PMC_16728343","title":"Increasing expression of GST-pi MIF, and ID1 genes in chemoresistant prostate cancer cells.","date":"2006","source":"Archives of andrology","url":"https://pubmed.ncbi.nlm.nih.gov/16728343","citation_count":17,"is_preprint":false},{"pmid":"20004020","id":"PMC_20004020","title":"Structural and functional comparison of MIF ortholog from Plasmodium yoelii with MIF from its rodent host.","date":"2009","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/20004020","citation_count":17,"is_preprint":false},{"pmid":"32705792","id":"PMC_32705792","title":"Macrophage inhibitory factor (MIF) gene polymorphisms are associated with disease susceptibility and with circulating MIF levels in active non-segmental vitiligo in patients from western Mexico.","date":"2020","source":"Molecular genetics & genomic medicine","url":"https://pubmed.ncbi.nlm.nih.gov/32705792","citation_count":17,"is_preprint":false},{"pmid":"23537651","id":"PMC_23537651","title":"Association between MIF gene polymorphisms and carotid artery atherosclerosis.","date":"2013","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/23537651","citation_count":16,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":47315,"output_tokens":6517,"usd":0.11985,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":15584,"output_tokens":5263,"usd":0.104747,"stage2_stop_reason":"end_turn"},"total_usd":0.224597,"stage1_batch_id":"msgbatch_01BbTCMyrRPyhtEq6b1MdwCN","stage2_batch_id":"msgbatch_011dEed5bbxYvTAaQWKJevxu","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2003,\n      \"finding\": \"CD74, a Type II transmembrane protein, is a high-affinity receptor for MIF. MIF binds to the extracellular domain of CD74 with a dissociation constant of ~9×10⁻⁹ M (by surface plasmon resonance), and CD74 is required for MIF-induced ERK1/2 MAP kinase activation, cell proliferation, and PGE2 production.\",\n      \"method\": \"Expression cloning, surface plasmon resonance (BIAcore), functional cell-based assays with soluble CD74 as inhibitor\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — expression cloning plus quantitative binding assay (SPR) plus functional rescue/inhibition experiments; widely replicated across multiple subsequent studies\",\n      \"pmids\": [\"12782713\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"Recombinant human and mouse MIF are bioactive 12.5 kDa proteins with no significant post-translational modifications; both inhibit monocyte migration, induce TNF-α secretion, and stimulate nitric oxide production by IFN-γ-primed macrophages. Circular dichroism reveals significant β-sheet and α-helix secondary structure.\",\n      \"method\": \"Recombinant protein expression and purification, gel electrophoresis, mass spectrometry, bioactivity assays (Boyden chamber, cytokine ELISA), circular dichroism spectroscopy, guanidine denaturation\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — multiple orthogonal biochemical and functional methods in a single rigorous study; foundational characterization replicated broadly\",\n      \"pmids\": [\"7947826\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"MIF triggers leukocyte recruitment through CXCR4; CD74 forms functional heteromeric complexes with CXCR4 at the cell surface of monocytes, and MIF-stimulated CD74-dependent AKT activation is blocked by anti-CXCR4 antibody and AMD3100, whereas CXCL12-stimulated AKT activation is not blocked by anti-CD74, indicating MIF-specific signaling through the CD74/CXCR4 complex.\",\n      \"method\": \"Co-immunoprecipitation of endogenous CD74/CXCR4 complexes from monocytes; HEK293 overexpression; receptor-specific antibody and small-molecule inhibitor blockade; AKT phosphorylation assay\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal co-IP from primary monocytes plus functional inhibition with two orthogonal blockers (antibody and AMD3100), single lab\",\n      \"pmids\": [\"19665027\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"MIF-induced neutrophil accumulation in the alveolar space is mediated through CD74 expressed on alveolar macrophages, which activates p44/p42 MAPK and chemokine (MIP-2) release; anti-CD74 antibody inhibits MIF-induced MAPK phosphorylation, MIP-2 release, and neutrophil accumulation in vivo.\",\n      \"method\": \"Intratracheal instillation of recombinant MIF in mice ± anti-CD74 antibody or ISO-1; macrophage culture; ELISA; BAL cell counting\",\n      \"journal\": \"Respiratory research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo and in vitro loss-of-function with defined cellular phenotype; single lab, two complementary readouts\",\n      \"pmids\": [\"19413900\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"CD74 acts as a functional receptor for MIF in human podocytes; MIF binding to CD74 leads to phosphorylation of ERK1/2 and p38, and MIF induces expression of TRAIL and MCP-1 in podocytes and proximal tubule cells in a p38-dependent manner. High glucose and TNF-α upregulate CD74 surface expression.\",\n      \"method\": \"Cell surface CD74 expression by flow cytometry; MIF stimulation of cultured podocytes; Western blot for ERK1/2 and p38 phosphorylation; cytokine ELISA; pharmacological inhibition of p38\",\n      \"journal\": \"Journal of the American Society of Nephrology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — cell-based mechanistic experiments with phosphorylation readouts and pharmacological pathway inhibition; single lab\",\n      \"pmids\": [\"18842989\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"MIF increases CD44 expression in synovial fibroblasts, promotes CD44 recruitment into a functional CD74/CD44 signal transduction complex, and stimulates alternative exon splicing to produce CD44v3-v6 isoforms associated with invasive phenotypes. CD44 recruitment, downstream MAPK and RhoA signaling, and invasive phenotype all require MIF and CD74.\",\n      \"method\": \"MIF stimulation of synovial fibroblasts; Western blot; co-immunoprecipitation; RT-PCR splicing analysis; RhoA activity assay; invasion assay; MIF pathway antagonist treatment and shRNA knockdown\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP plus functional rescue/inhibition with multiple readouts; single lab, human allele correlation\",\n      \"pmids\": [\"27872288\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"MIF-CD74 signaling inhibits IFN-γ secretion in microglia through phosphorylation of ERK1/2, thereby suppressing microglial M1 polarization; siRNA-mediated knockdown or antibody neutralization of MIF or CD74 promotes IFN-γ release, induces M2→M1 shift, and prolongs survival in glioma-implanted mice.\",\n      \"method\": \"siRNA knockdown; antibody neutralization; Western blot for ERK1/2 phosphorylation; cytokine ELISA; in vivo glioma implantation model; survival analysis\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro mechanistic signaling data combined with in vivo functional validation; single lab\",\n      \"pmids\": [\"27157615\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"MIF secretion is induced by cell adhesion to fibronectin in quiescent fibroblasts; secreted MIF acts as an autocrine mediator of integrin-dependent MAP kinase activation, cyclin D1 expression, and DNA synthesis. MIF secretion requires protein kinase C activity, and MIF-deficient cells show significantly higher Rb tumor suppressor and lower E2F transcriptional activities.\",\n      \"method\": \"MIF-null mouse fibroblasts; recombinant MIF reconstitution; PKC inhibition; Western blot; cyclin D1 reporter; DNA synthesis assay; Rb/E2F activity assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO cells with reconstitution and pharmacological inhibition; single lab, multiple readouts\",\n      \"pmids\": [\"12297513\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"MIF is O-GlcNAcylated at Ser112/Thr113 at its C-terminus; the naturally secreted O-GlcNAcylated MIF binds to EGFR and inhibits EGF binding and EGF-induced EGFR activation, ERK and c-Jun phosphorylation, cell invasion, proliferation, and brain tumor formation. EGFR activation enhances secretion of MMP13, which degrades extracellular MIF, creating a feedforward loop.\",\n      \"method\": \"Mass spectrometry identification of O-GlcNAcylation site; binding assays (MIF-EGFR interaction); functional assays (proliferation, invasion, tumor formation); site-directed mutagenesis at Ser112/Thr113; MMP13 secretion assay\",\n      \"journal\": \"Nature cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — mass spectrometry PTM identification, mutagenesis, in vitro binding, and in vivo tumor model; single lab but multiple orthogonal methods\",\n      \"pmids\": [\"26280537\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"MIF is a 3' flap nuclease that translocates to the nucleus during S phase; PARP1 co-localizes with MIF at the DNA replication fork, and MIF nuclease activity is required to resolve replication stress. MIF loss causes increased mutation frequency, cell cycle delays, and inhibition of DNA synthesis that cannot be rescued by nuclease-deficient MIF mutant.\",\n      \"method\": \"In vitro nuclease assay; nuclear fractionation; co-localization by imaging; cell cycle analysis; DNA synthesis assay; mutant MIF rescue experiment; cancer cell MIF knockdown\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro enzymatic reconstitution with mutagenesis validation plus cell-based rescue experiments using nuclease-dead mutant; single lab but multiple methods\",\n      \"pmids\": [\"34012010\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"The transcription factor ICBP90 (UHRF1) is the major nuclear protein interacting with the MIF -794 CATT5-8 microsatellite promoter region and is essential for MIF transcription in monocytes/macrophages, B and T lymphocytes, and synovial fibroblasts; TLR-induced MIF transcription is regulated in an ICBP90- and CATT repeat length-dependent manner.\",\n      \"method\": \"Oligonucleotide affinity chromatography; LC-MS/MS protein identification; ICBP90 shRNA knockdown; promoter reporter assays; whole-genome transcription analysis\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — affinity chromatography + mass spectrometry identification, shRNA functional validation, genome-wide transcriptomic confirmation; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"26752645\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Hypoxia-induced MIF expression is driven by HIF-1α through a hypoxia response element (HRE) in the 5'UTR of the MIF gene, and this expression is further modulated by CREB; hypoxia-induced degradation of CREB amplifies HIF-1-driven MIF transcription.\",\n      \"method\": \"HIF-1α overexpression; HRE reporter assay; CREB expression modulation; promoter deletion analysis; RT-PCR\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — promoter reporter assays with deletion constructs and defined transcription factor manipulation; single lab\",\n      \"pmids\": [\"16854377\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Soluble CD74 (sCD74) reroutes MIF/CXCR4/AKT-mediated survival of cardiac myofibroblasts to necroptosis via RIP1/RIP3-dependent pathway; sCD74 diminishes MIF-mediated AKT activation and triggers p38 activation, and co-treatment with MIF and sCD74 induces interferon-stimulated gene upregulation.\",\n      \"method\": \"Recombinant MIF + sCD74 co-treatment of primary cardiac fibroblasts; Western blot for AKT and p38; RIP1/RIP3 inhibitor studies; microarray + RT-qPCR gene expression\",\n      \"journal\": \"Journal of the American Heart Association\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — primary cell mechanistic experiments with pharmacological pathway inhibition and gene expression profiling; single lab\",\n      \"pmids\": [\"30371153\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"MIF directly binds to and inhibits the proteolytic activity of the serine protease HTRA1, making MIF the first identified endogenous inhibitor of HTRA1. Both proteins are co-expressed in astrocytes and the interaction modulates availability of growth factors and extracellular matrix molecules affecting cell growth and differentiation.\",\n      \"method\": \"Co-immunoprecipitation; in vitro protease activity assay with MIF as inhibitor; immunohistochemistry co-localization in astrocytes\",\n      \"journal\": \"Cellular and molecular life sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP binding identification plus in vitro enzymatic inhibition assay; single lab, two orthogonal methods\",\n      \"pmids\": [\"28726057\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"HDAC6 deacetylates MIF at K78; HDAC6 inhibition or aspirin treatment promotes MIF acetylation at K78, which suppresses the interaction between MIF and AIF (apoptosis-inducing factor), thereby impairing MIF nuclear translocation in ischemic cortical neurons and reducing neuronal DNA fragmentation and death.\",\n      \"method\": \"Mass spectrometry identification of K78 acetylation; co-immunoprecipitation of MIF-AIF interaction; MIF K78Q acetylation-mimetic knock-in mice; HDAC6 genetic ablation and pharmacological inhibition; fractionation for nuclear localization\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — MS-identified PTM site confirmed by mutagenesis knock-in mice, co-IP interaction studies, and subcellular fractionation; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"35585040\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"MIF directly binds PINK1, disrupting the PINK1-Parkin protein interaction; this blocks Parkin recruitment to mitochondria and inhibits mitophagy initiation in renal tubular epithelial cells, leading to apoptosis that can be reversed by the MIF inhibitor ISO-1.\",\n      \"method\": \"Co-immunoprecipitation of MIF-PINK1 interaction; MIF inhibition (ISO-1) and overexpression; Western blot for PINK1-Parkin interaction; mitophagy flux assays; apoptosis assay\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct protein interaction by co-IP combined with functional rescue; single lab\",\n      \"pmids\": [\"38956064\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"RORα (nuclear receptor) directly occupies the MIF promoter region in THP-1 monocytes and HUVEC cells, and RORα ligand treatment modulates MIF expression, identifying MIF as a direct transcriptional target of RORα.\",\n      \"method\": \"Chromatin immunoprecipitation (ChIP) assay; RORα-specific ligand (CPG 52608, SR1001) treatment; RT-PCR gene expression analysis\",\n      \"journal\": \"Cell biology international\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP demonstrates direct promoter occupancy and ligand treatment confirms functional regulation; single lab\",\n      \"pmids\": [\"27925372\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"MIF and its homolog D-DT synergistically inhibit steady-state p53 phosphorylation, stabilization, and transcriptional activity; combined siRNA loss of MIF and D-DT leads to dramatically reduced cell cycle progression, anchorage independence, focus formation, and increased apoptosis compared to individual loss. The p53 activation is dependent on reactive oxygen species (ROS) that mediate aberrant AMPK activation in MIF/D-DT-deficient cells.\",\n      \"method\": \"siRNA dual knockdown of MIF and D-DT; Western blot for p53 phosphorylation; cell cycle analysis; focus formation and soft-agar assays; ROS measurement; AMPK inhibitor experiments\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic loss-of-function with multiple functional readouts and pathway dissection; single lab\",\n      \"pmids\": [\"24932684\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"MIF loss delays Myc-induced B-cell lymphoma development in vivo by perturbing E2F DNA-binding activity and enhancing p53 pathway tumor suppressor activity; MIF-deficient premalignant B-cells show delayed S-phase progression and increased apoptosis, and MIF-deficient lymphomas that do arise carry ARF deletions and p53 inactivating mutations.\",\n      \"method\": \"Eμ-Myc lymphoma mouse model with MIF-null background; E2F DNA-binding activity assay; p53 pathway activity; cell cycle analysis; tumor onset kinetics\",\n      \"journal\": \"Cell death and differentiation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis in vivo with molecular mechanism (E2F/p53) characterization; single lab\",\n      \"pmids\": [\"15947793\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"MIF acts as an autocrine growth factor in pancreatic cancer cells; siRNA-mediated MIF silencing reduces MIF protein >85%, inhibits cellular proliferation, induces apoptosis, and is accompanied by increased AKT phosphorylation at Thr308.\",\n      \"method\": \"siRNA knockdown; qRT-PCR; Western blot; FACS apoptosis assay; AKT phosphorylation Western blot\",\n      \"journal\": \"The Journal of surgical research\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single-method KD with phenotype but limited pathway mechanistic depth; single lab\",\n      \"pmids\": [\"19726058\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"CD74 is upregulated on activated CD4+ T cells by post-translational modification (chondroitin sulfate addition) and can be detected on the cell surface; CD74/CXCR4 heterocomplexes on activated CD4+ T cells are visualized by proximity ligation assay, and both CD74 and CXCR4 are causally involved in MIF-induced CD4+ T-cell migration as shown by receptor-specific inhibitors in 3D live cell imaging.\",\n      \"method\": \"Flow cytometry; Western blot; proximity ligation assay; 3D-matrix live cell imaging; receptor-specific pathway inhibitors; reanalysis of RNA-seq and proteomics datasets\",\n      \"journal\": \"Cellular and molecular life sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — proximity ligation for complex detection combined with functional migration assay using inhibitors; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"38992165\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"CD74 is required for MIF's inhibitory effect on osteoclastogenesis; MIF inhibits osteoclast formation from wild-type but not CD74-knockout bone marrow cultures, and CD74-deficient mice show decreased bone mass, increased osteoclast number and area, and reduced NFATc1 and c-Fos expression upon MIF treatment.\",\n      \"method\": \"CD74 knockout mice; in vitro osteoclast differentiation assay; micro-CT; histomorphometry; Western blot for NFATc1 and c-Fos\",\n      \"journal\": \"Journal of bone and mineral research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO with in vitro rescue and in vivo bone phenotype, molecular pathway confirmation; single lab\",\n      \"pmids\": [\"23044992\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Endothelial cell-derived MIF decreases pericyte contractility by reducing myosin light chain phosphorylation and increases intercellular pericyte gap formation, thereby enhancing neutrophil transmigration; EC-specific MIF knockout mice show decreased neutrophil infiltration to BAL and lung tissue and increased myosin light chain phosphorylation in pericytes in acute lung injury.\",\n      \"method\": \"EC-specific MIF conditional knockout mice; in vitro microvascular model; myosin light chain phosphorylation Western blot; silicone substrate contractility assay; bronchoalveolar lavage cell counting\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — cell-type-specific KO with defined molecular mechanism and in vivo validation; single lab\",\n      \"pmids\": [\"30252532\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"MIF induces MIP-2 accumulation in alveolar macrophages through p44/p42 MAPK activation downstream of CD74; MIF-induced MAPK phosphorylation and MIP-2 release by macrophages are blocked by anti-CD74 antibody.\",\n      \"method\": \"Macrophage culture; MIF stimulation; anti-CD74 antibody blockade; Western blot for p44/p42 MAPK phosphorylation; ELISA for MIP-2\",\n      \"journal\": \"Respiratory research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — cell-based signaling with antibody blockade of defined receptor; single lab, mechanistic clarity\",\n      \"pmids\": [\"19413900\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"4-IPP (MIF inhibitor) blocks MIF/CD74 internalization, activates JNK, dose-dependently inhibits proliferation, and induces apoptosis and mitotic cell death in thyroid carcinoma cells co-expressing MIF and CD74; effects are partially reduced in CD74-negative cells.\",\n      \"method\": \"4-IPP pharmacological inhibition; cell viability assay; Western blot for JNK activation; flow cytometry for apoptosis; immunohistochemistry of patient samples\",\n      \"journal\": \"Endocrine-related cancer\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — pharmacological inhibitor with defined receptor co-expression context but relying on a non-specific small molecule; single lab\",\n      \"pmids\": [\"26206776\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"MIF is a constitutively expressed, secreted 12.5 kDa cytokine that signals extracellularly through a primary receptor complex composed of CD74 (high-affinity binding partner, Kd ~9 nM) together with co-receptors CD44 and CXCR4/CXCR2, activating ERK1/2, AKT, p38, and RhoA downstream pathways to drive inflammation, cell proliferation, and survival; intracellularly, MIF functions as a 3' flap nuclease at replication forks (requiring nuclear translocation in S phase), suppresses p53 activity, binds PINK1 to block mitophagy, and its activity is regulated by HDAC6-mediated acetylation at K78 (which prevents MIF–AIF interaction and nuclear translocation); its transcription is driven by HIF-1α through an HRE element and by the transcription factor ICBP90/UHRF1 acting at the polymorphic −794 CATT microsatellite, while glucocorticoids paradoxically induce MIF secretion via GRE/ATF-CRE elements, allowing MIF to counter-regulate glucocorticoid immunosuppression.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"MIF is a constitutively expressed, secreted ~12.5 kDa cytokine that drives inflammation, leukocyte recruitment, and cell proliferation/survival by signaling extracellularly through the high-affinity receptor CD74 (Kd ~9 nM), which is required for MIF-induced ERK1/2 activation, proliferation, and PGE2 production [#0, #1]. At the cell surface CD74 assembles with co-receptors to form functional signaling complexes: CD74/CXCR4 heterocomplexes mediate MIF-specific AKT activation and leukocyte/CD4+ T-cell migration [#2, #20], while MIF recruits CD44 into a CD74/CD44 complex that drives MAPK and RhoA signaling and an invasive phenotype [#5]. Through these receptor complexes MIF activates ERK1/2, p38, AKT, and RhoA in diverse cell types—podocytes, macrophages, microglia, and fibroblasts—to control chemokine output (e.g., MIP-2), TRAIL/MCP-1 induction, macrophage polarization, and adhesion-dependent cyclin D1 expression and DNA synthesis [#3, #4, #6, #7, #23]. MIF also functions independently of CD74 as an autocrine growth factor, suppressing the Rb/E2F and p53 tumor-suppressor axes: loss of MIF (together with its homolog D-DT) restores p53 phosphorylation and activity via ROS-driven AMPK activation, and MIF loss delays Myc-induced lymphomagenesis by perturbing E2F and enhancing p53 function [#7, #17, #18]. Intracellularly, MIF acts as a 3' flap nuclease that translocates to the nucleus in S phase and co-localizes with PARP1 at replication forks to resolve replication stress, with nuclease-dead MIF failing to rescue DNA synthesis defects [#9]. MIF activity is set by post-translational modification: HDAC6 deacetylates MIF at K78 to permit MIF–AIF interaction and nuclear translocation in ischemic neurons [#14], and C-terminal O-GlcNAcylation directs a secreted MIF pool that binds EGFR to antagonize EGF signaling [#8]. MIF additionally binds PINK1 to block PINK1–Parkin coupling and mitophagy [#15] and is the first identified endogenous inhibitor of the serine protease HTRA1 [#13]. MIF transcription is controlled by ICBP90/UHRF1 acting at the polymorphic −794 CATT microsatellite [#10], by HIF-1α through a hypoxia response element [#11], and by the nuclear receptor RORα [#16].\",\n  \"teleology\": [\n    {\n      \"year\": 1994,\n      \"claim\": \"Established MIF as a defined, bioactive protein rather than a crude activity, anchoring all subsequent mechanism: recombinant MIF is a 12.5 kDa, structured protein with intrinsic immunoregulatory function.\",\n      \"evidence\": \"Recombinant human/mouse MIF expression, mass spectrometry, circular dichroism, and bioactivity assays (migration inhibition, TNF-α, nitric oxide)\",\n      \"pmids\": [\"7947826\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No receptor or signaling mechanism identified\", \"Secretion route and structural basis of activity not defined\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Showed MIF is a secreted autocrine mediator of growth signaling, linking it to cell-cycle control via the Rb/E2F axis before its receptor was known.\",\n      \"evidence\": \"MIF-null mouse fibroblasts with recombinant reconstitution, PKC inhibition, cyclin D1 reporter, Rb/E2F activity assays\",\n      \"pmids\": [\"12297513\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Receptor mediating autocrine MIF action not identified here\", \"Mechanism connecting secreted MIF to Rb/E2F not resolved\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Identified the high-affinity MIF receptor, converting MIF from an orphan cytokine into a defined receptor-ligand signaling system.\",\n      \"evidence\": \"Expression cloning, surface plasmon resonance binding (Kd ~9 nM), and CD74-dependent ERK1/2 / proliferation / PGE2 assays\",\n      \"pmids\": [\"12782713\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"CD74 lacks an intracellular signaling domain — co-receptor requirement unaddressed\", \"Quantitative contribution of CD74 vs other binding partners not resolved\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Demonstrated in vivo that MIF promotes tumorigenesis through tumor-suppressor circuits, establishing the E2F/p53 axis as a key MIF effector pathway.\",\n      \"evidence\": \"Eμ-Myc lymphoma model on MIF-null background, E2F DNA-binding and p53 pathway assays, tumor onset kinetics\",\n      \"pmids\": [\"15947793\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular link between MIF and E2F/p53 regulation not mechanistically defined\", \"Does not distinguish secreted vs intracellular MIF activity\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Defined transcriptional control of MIF under hypoxia, explaining inducible MIF expression in low-oxygen tissue contexts.\",\n      \"evidence\": \"HIF-1α overexpression, HRE reporter and promoter deletion assays, CREB modulation\",\n      \"pmids\": [\"16854377\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Relative contribution of HIF-1α vs other promoter elements in vivo not quantified\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Resolved the co-receptor problem by showing CD74 partners with CXCR4 (and engages p44/p42 MAPK in macrophages), explaining how the signaling-incompetent CD74 transduces MIF signals to AKT and chemokine output.\",\n      \"evidence\": \"Co-IP of endogenous CD74/CXCR4, AMD3100/antibody blockade, AKT phosphorylation, and in vivo MIF-induced alveolar neutrophil/MIP-2 assays\",\n      \"pmids\": [\"19665027\", \"19413900\", \"19726058\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Stoichiometry of the CD74/CXCR4 complex not defined\", \"Autocrine MIF growth role in pancreatic cancer rests on single-method knockdown\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Showed MIF and its homolog D-DT cooperatively suppress p53, providing a mechanistic basis for MIF's oncogenic survival function via ROS/AMPK.\",\n      \"evidence\": \"Dual siRNA knockdown of MIF and D-DT, p53 phosphorylation Western blots, ROS measurement, AMPK inhibitor experiments, transformation assays\",\n      \"pmids\": [\"24932684\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct biochemical target of MIF/D-DT upstream of ROS not identified\", \"Functional redundancy boundaries between MIF and D-DT unresolved\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Identified a C-terminal O-GlcNAcylation that diverts secreted MIF to antagonize EGFR, revealing PTM-gated functional specialization of MIF pools.\",\n      \"evidence\": \"Mass spectrometry PTM mapping, Ser112/Thr113 mutagenesis, MIF-EGFR binding, invasion/proliferation/tumor assays, MMP13 secretion\",\n      \"pmids\": [\"26280537\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Enzyme adding the O-GlcNAc and its regulation not defined\", \"Balance between EGFR-antagonist and CD74-agonist MIF pools in vivo unknown\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Expanded the receptor repertoire (CD44) and identified the dominant transcriptional driver ICBP90/UHRF1 at the disease-associated −794 CATT microsatellite, plus RORα as a direct regulator, connecting MIF genetics to expression.\",\n      \"evidence\": \"Co-IP of CD74/CD44, RhoA and invasion assays; affinity chromatography + LC-MS/MS and shRNA for ICBP90; ChIP and ligand assays for RORα; microglial signaling assays\",\n      \"pmids\": [\"27872288\", \"26752645\", \"27925372\", \"27157615\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Interplay among CD74/CXCR4/CD44 receptor configurations not unified\", \"How CATT repeat length mechanistically alters ICBP90 binding not resolved\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Identified MIF as the first endogenous HTRA1 inhibitor, adding a protease-regulatory function distinct from cytokine signaling.\",\n      \"evidence\": \"Co-IP, in vitro protease inhibition assay, astrocyte co-localization by immunohistochemistry\",\n      \"pmids\": [\"28726057\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Structural basis of MIF–HTRA1 inhibition not determined\", \"Physiological consequences of the interaction not established in vivo\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Defined cell-type-specific and context-dependent MIF signaling outputs—endothelial MIF relaxing pericytes for neutrophil transit, and soluble CD74 rerouting MIF/CXCR4 survival signaling to necroptosis.\",\n      \"evidence\": \"EC-specific MIF conditional KO with myosin light chain phosphorylation and BAL counts; sCD74+MIF co-treatment of cardiac fibroblasts with RIP1/RIP3 inhibitors and gene profiling\",\n      \"pmids\": [\"30252532\", \"30371153\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism by which sCD74 switches AKT survival to RIP1/RIP3 death not defined\", \"Receptor configuration for endothelial MIF effect on pericytes not mapped\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Revealed an intracellular enzymatic function—MIF is a 3' flap nuclease acting at replication forks—establishing a moonlighting role wholly distinct from cytokine signaling.\",\n      \"evidence\": \"In vitro nuclease assay, nuclear fractionation, PARP1 co-localization, and nuclease-dead mutant rescue in MIF-knockdown cancer cells\",\n      \"pmids\": [\"34012010\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Trigger for S-phase nuclear translocation not defined\", \"Relationship between nuclease and cytokine functions of the same protein unresolved\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Showed that K78 acetylation status, controlled by HDAC6, gates MIF–AIF binding and nuclear translocation, providing a switch governing MIF's intracellular pro-death function.\",\n      \"evidence\": \"Mass spectrometry K78 acetylation mapping, MIF-AIF co-IP, K78Q knock-in mice, HDAC6 ablation/inhibition, nuclear fractionation in ischemic neurons\",\n      \"pmids\": [\"35585040\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Acetyltransferase opposing HDAC6 not identified\", \"Link between K78-controlled AIF binding and the flap-nuclease function not integrated\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Added a mitochondrial quality-control role: MIF binds PINK1 to block PINK1–Parkin coupling and mitophagy, expanding MIF's intracellular interactome and cell-death control.\",\n      \"evidence\": \"MIF-PINK1 co-IP, ISO-1 inhibition and overexpression, mitophagy flux and apoptosis assays in renal tubular cells; PLA visualization of CD74/CXCR4 on CD4+ T cells\",\n      \"pmids\": [\"38956064\", \"38992165\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether PINK1 binding requires specific MIF PTMs or localization not addressed\", \"Direct vs indirect mechanism of PINK1–Parkin disruption not resolved\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How a single small protein partitions between secreted cytokine, intracellular flap nuclease, protease inhibitor, and mitophagy regulator—and how PTMs (O-GlcNAc, K78 acetylation) coordinate these fates—remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified model linking MIF's enzymatic and signaling functions\", \"No structural framework integrating receptor binding, nuclease activity, and protein-interaction surfaces\", \"Tissue-level balance of pro- vs anti-tumor and pro- vs anti-survival MIF activities undefined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140097\", \"supporting_discovery_ids\": [9]},\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [0, 1, 2, 5]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [13, 15]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [0, 2]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [0, 1, 7, 8]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [9, 14]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [14, 15]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [0, 1, 3, 6, 23]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 2, 4, 5]},\n      {\"term_id\": \"R-HSA-73894\", \"supporting_discovery_ids\": [9]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [14, 15]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [10, 11, 16]}\n    ],\n    \"complexes\": [\"CD74/CXCR4 receptor complex\", \"CD74/CD44 receptor complex\"],\n    \"partners\": [\"CD74\", \"CXCR4\", \"CD44\", \"PARP1\", \"EGFR\", \"HTRA1\", \"PINK1\", \"AIF\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":8,"faith_total":8,"faith_pct":100.0}}